Mivebresib

DB21300InvestigationalSmall molecule

Mivebresib is a small molecule drug. The usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family... Mivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis).

Mechanism: Pharmacologically active on Bromodomain-containing protein 4, Bromodomain-containing protein 2, and Bromodomain-containing protein 3
Curator reviewed
Formula / weight: C₂₂H₁₉F₂N₃O₄S · 459.47 g/mol (avg)
Code names: ABBV-075

Resolves to

Compound

UNIIVR86R11J7JCAS1445993-26-9ChEMBLCHEMBL3987016ChEBI756028PubChem71600087

Structure

InChIKeyRDONXGFGWSSFMY-UHFFFAOYSA-NSMILESCCS(=O)(=O)NC1=CC(=C(OC2=C(F)C=C(F)C=C2)C=C1)C1=CN(C)C(=O)C2=C1C=CN2

Targets

O60885BRD4P25440BRD2Q15059BRD3

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mivebresib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account